Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating) – Equities researchers at SVB Leerink dropped their Q2 2022 earnings estimates for Tandem Diabetes Care in a research report issued to clients and investors on Monday, April 18th. SVB Leerink analyst D. Antalffy now forecasts that the medical device company will post earnings of $0.12 per share for the quarter, down from their previous estimate of $0.14. SVB Leerink has a “Market Perform” rating on the stock. SVB Leerink also issued estimates for Tandem Diabetes Care’s Q3 2022 earnings at $0.14 EPS, FY2022 earnings at $0.55 EPS, Q2 2023 earnings at $0.40 EPS, Q3 2023 earnings at $0.39 EPS and FY2023 earnings at $1.59 EPS.
Other research analysts have also recently issued research reports about the company. Citigroup lowered their target price on Tandem Diabetes Care from $163.00 to $155.00 and set a “buy” rating for the company in a research note on Wednesday, February 23rd. Wells Fargo & Company lifted their price objective on Tandem Diabetes Care from $160.00 to $166.00 and gave the company an “overweight” rating in a research note on Wednesday, February 23rd. StockNews.com assumed coverage on Tandem Diabetes Care in a research note on Thursday, March 31st. They set a “hold” rating for the company. Zacks Investment Research cut Tandem Diabetes Care from a “hold” rating to a “sell” rating and set a $108.00 price objective for the company. in a research note on Wednesday, March 16th. Finally, Bank of America assumed coverage on Tandem Diabetes Care in a research note on Wednesday, March 2nd. They set a “neutral” rating and a $130.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $140.91.
Tandem Diabetes Care (NASDAQ:TNDM – Get Rating) last posted its quarterly earnings results on Tuesday, February 22nd. The medical device company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by ($0.04). Tandem Diabetes Care had a return on equity of 4.58% and a net margin of 2.21%. The company had revenue of $210.00 million for the quarter, compared to the consensus estimate of $198.83 million. During the same quarter in the previous year, the business earned $0.24 earnings per share. Tandem Diabetes Care’s revenue was up 24.9% compared to the same quarter last year.
In other Tandem Diabetes Care news, Director Rebecca B. Robertson sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, February 1st. The stock was sold at an average price of $117.97, for a total value of $176,955.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kathleen Mcgroddy-Goetz sold 405 shares of the company’s stock in a transaction that occurred on Monday, March 14th. The stock was sold at an average price of $106.00, for a total value of $42,930.00. The disclosure for this sale can be found here. Insiders sold 8,905 shares of company stock valued at $992,325 in the last ninety days. 4.80% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. boosted its stake in Tandem Diabetes Care by 11.6% in the 4th quarter. BlackRock Inc. now owns 6,478,638 shares of the medical device company’s stock worth $975,164,000 after purchasing an additional 672,004 shares during the period. Capital World Investors boosted its stake in Tandem Diabetes Care by 4.0% in the 4th quarter. Capital World Investors now owns 3,427,129 shares of the medical device company’s stock worth $515,851,000 after purchasing an additional 133,133 shares during the period. Invesco Ltd. boosted its stake in Tandem Diabetes Care by 11.8% in the 4th quarter. Invesco Ltd. now owns 1,942,971 shares of the medical device company’s stock worth $292,456,000 after purchasing an additional 205,453 shares during the period. State Street Corp boosted its stake in Tandem Diabetes Care by 2.2% in the 4th quarter. State Street Corp now owns 1,648,252 shares of the medical device company’s stock worth $248,095,000 after purchasing an additional 35,825 shares during the period. Finally, RTW Investments LP boosted its stake in Tandem Diabetes Care by 1.2% in the 3rd quarter. RTW Investments LP now owns 1,160,734 shares of the medical device company’s stock worth $138,568,000 after purchasing an additional 13,326 shares during the period. Institutional investors and hedge funds own 97.11% of the company’s stock.
Tandem Diabetes Care Company Profile (Get Rating)
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
- Get a free copy of the StockNews.com research report on Tandem Diabetes Care (TNDM)
- 3 No-Brainer Stocks to Buy with $1000
- Rite Aid Stock is Getting Cheap Enough to Buy Here
- Analysts Reel In Netflix Targets Ahead Of Q1 Earnings
- MarketBeat Podcast: Making Money in the Red-Hot Housing Market
- Banking On Bank Of America
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.